Track topics on Twitter Track topics that are important to you
Since Chris Viehbacher joined sanofi-aventis as CEO his aim has been to get the company recognised as a global healthcare company and not solely as a producer of vaccines. Jean-Claude Muller, Senior V...
Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression...
The exclusive Life Science Leader interview with Gregory Irace, president and CEO of sanofi-aventis U.S. By Dan Schell, Life Science Leader magazine
Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH
Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...
Merck & Co. and sanofi-aventis target US$ 19B market
Sanofi-aventis pact with CureDM to develop novel diabetes drug
Sanofi-aventis buys Polish consumer healthcare group Nepentes
Dendreon's Provenge and sanofi-aventis' Cabazitaxel show positive data
Allegra-D 12 Hour Allergy and Congestion
Allegra-D 12 Hour Allergy and Congestion
HIPREX(methenamine hippurate tablets USP)
To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME).
Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-VAX) licensed in the United States, has announced that their stock of YF-VAX is totally depleted as of July 24, 2017. YF-VAX for c...
Recent manufacturing problems resulted in a shortage of the only U.S.-licensed yellow fever vaccine. This shortage is expected to lead to a complete depletion of yellow fever vaccine available for the...
This case commentary examines the CJEU's recent decision in C-621/15 W and Others v Sanofi Pasteur MSD SNC  ECR I. This commentary critically examines the decision through the lens of the cultur...
This paper studies the Generalized Mahalanobis Distance (GMD) approach proposed by Hoffelder(1) which measures the dissimilarity of two multivariate Gaussian distributions with arbitrary covariance ma...
The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antith...
To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in postoperative cardiac surgery patients by comparing plasma anti-Xa activity when enoxaparin is administered ...
A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis
A randomized, double-blind, placebo-controlled parallel-group study, comparing the bioequivalence of triamcinolone acetonide aqueous nasal spray (Apotex, Inc.) to that of Nasacort® AQ nas...
The primary objective of the study is to determine whether eszopiclone (Eurofarma) is non-inferior to the reference drug zopiclone (Imovane®, Sanofi-Aventis) in the treatment of insomnia.
Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...
Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SA...
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Pa...
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales.
We have published hundreds of sanofi-aventis U.S. LLC news stories on BioPortfolio along with dozens of sanofi-aventis U.S. LLC Clinical Trials and PubMed Articles about sanofi-aventis U.S. LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of sanofi-aventis U.S. LLC Companies in our database. You can also find out about relevant sanofi-aventis U.S. LLC Drugs and Medications on this site too.